A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

被引：0
|
作者：
Scheulen, M. [1 ]
Mross, K. [2 ]
Richly, H. [1 ]
Nokay, B. [1 ]
Frost, A. [2 ]
Scharr, D. [2 ]
Lee, K. H. [3 ]
Saunders, O. [3 ]
Hilbert, J. [4 ]
Fietz, O. [3 ]
机构：
[1] Univ Essen Gesamthsch, W German Canc Ctr, Innere Klin Tumorforsch, Essen, Germany
[2] Univ Freiburg, Tumour Biol Ctr, Freiburg, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Clin Res, Biberach, Germany
[4] Boehringer Ingelheim Pharmaceut Inc, Clin Pharmacokinet Pharmacodynam, Ridgefield, CT USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72203-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [31] A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Naing, A.
    Klevesath, M. B.
    Mattiacci, M. R.
    Di Cara, A.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158
  • [32] Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
    Van Cutsem, Eric
    Khayat, David
    Verslype, Chris
    Billemont, Bertrand
    Tejpar, Sabine
    Meric, Jean-Baptiste
    Soussan-Lazard, Karen
    Assadourian, Sylvie
    Cartot-Cotton, Sylvaine
    Rixe, Olivier
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 17 - 24
  • [33] A phase 1 study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
    Rasschaert, M.
    Schrijvers, D.
    Van den Brande, J.
    Dyck, J.
    Bosmans, J.
    Merkle, K.
    Vermorken, J. B.
    BRITISH JOURNAL OF CANCER, 2007, 96 (11) : 1692 - 1698
  • [34] A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours
    Schoeffski, P.
    Awada, A.
    Dumez, H.
    Gil, T.
    Bartholomeus, S.
    Selleslach, J.
    Taton, M.
    Fritsch, H.
    Peter, N.
    Munzert, G.
    EJC SUPPLEMENTS, 2008, 6 (12): : 14 - 15
  • [35] Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors
    Nemunaitis, J. J.
    Senzer, N. N.
    Kurzrock, R.
    Ng, C. S.
    Das, A.
    Atienza, R. S.
    Zang, E. A.
    Jansen, M.
    Ashworth, S.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies
    Sonet, Anne
    Graux, Carlos
    Maertens, Johan
    Hartog, Christine-Maria
    Duyster, Justus
    Goetze, Katharina
    Greiner, Jochen
    Huetter, Marie-Luise
    Gratwohl, Alois
    Heim, Dominik
    Hess, Dagmar
    Chalandon, Yves
    Gianella-Borradori, Athos
    Rejeb, Narmyn
    Ottmann, Oliver
    BLOOD, 2008, 112 (11) : 1018 - 1018
  • [37] A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours.
    Hofheinz, R.
    Hochhaus, A.
    Al-Batran, S.
    Nanci, A.
    Reichardt, V.
    Trommeshauser, D.
    Hoffmann, M.
    Steegmaier, M.
    Munzert, G.
    Jäger, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 88S - 88S
  • [38] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Li, Xiaoyu
    Qiu, Meng
    Wang, ShengJun
    Zhu, Hong
    Feng, Bi
    Zheng, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 593 - 604
  • [39] A phase I dose-escalation study of RAD001 administered daily to Japanese patients with advanced solid tumors
    Doi, T.
    Ohtsu, A.
    Nakagawa, K.
    Okamoto, I.
    Kurei, K.
    Kobayashi, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 114 - 114
  • [40] A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours
    El-Helali, A.
    Plummer, R.
    Jayson, G.
    Coyle, V.
    Drew, Y.
    Mescallado, N.
    Harris, N.
    Clamp, A.
    McCann, J.
    Kennedy, R.
    Cranston, A.
    Wilson, R.
    ANNALS OF ONCOLOGY, 2017, 28
12345